02 May 2003
Role of PARP activation in the acute respiratory distress syndrome (ARDS)
L. LiaudetMed Sci Monit 2003; 9(1): 35-0 :: ID: 15098
Abstract
The acute respiratory distress syndrome (ARDS) is a severe form of pulmonary inflammation arising as a complication of local (pneumonia, smoke inhalation, aspiration), or systemic (sepsis, trauma, burn injury and pancreatitis) inflammatory processes. The main features of ARDS are diffuse alveolar damage, high permeabiltity pulmonary edema, inflammatory cell infiltration, and loss of surfactant production, resulting in severe disturbances of lung mechanics and gas exchanges. Recent investigations support the concept that activation of PARP, secondary to locally produced oxygen- and nitrogen-derived free radicals and oxidants, may represent a key mechanism of pulmonary inflammation and lung injury in experimental ARDS. In vitro, PARP is activated in response to oxidant-driven DNA damage in respiratory epithelial cells, leading to bioenergetic failure and necrotic cell death [1]. PARP activation also plays a role in the loss of surfactant production by type II pneumocytes exposed to hydrogen peroxide [2]. In vivo, the PARP inhibitor 5-aminoisoquinoline reduced the degree of lung injury and pulmonary neutrophil infiltration in rats challenged by intra-thoracic zymosan-activated plasma, via a mechanism involving a reduced expression of endothelial P-selectin and ICAM-1 [3]. In a murine model of ARDS triggered by the intratracheal instillation of endotoxin, PARP suppression (either by genetic deletion or pharmacological inhibition with PJ-34) markedly reduced the local release of pro-inflammatory cytokines (TNFa, IL-1b and IL-6), and chemokines (MIP-1a and MIP-2), resulting in a lesser degree of neutrophil accumulation and pulmonary edema, as well as in an improved histological status [4]. Thus, oxidant-triggered activation of PARP mediates lung epithelial cell damage and dysfunction, and also represents a central mechanism regulating leukocyte trafficking and the expression of pro-inflammatory mediators within the injured lung. These observations suggest that the pharmacological inhibition of PARP might be useful in clinical conditions associated with overwhelming lung inflammation such as ARDS. References: 1.Nanavaty UB et al: Exp Lung Res, 2002; 28: 591-607 2.Hudak BB et al: Am J Physiol, 1995; 269: L59-64 3.Cuzzocrea S et al: Biochem Pharmacol, 2002; 63: 293-304 4.Liaudet L et al: Am J Respir Crit Care Med, 2002; 165: 372-7
Keywords: ARDS, PARP, neutrophil
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Intradialytic Exercise: Effects on Arterial Stiffness and Gait Speed in Patients Undergoing HemodialysisMed Sci Monit In Press; DOI: 10.12659/MSM.947604
Clinical Research
Use of The Mirror-Image Technique for Patient-Specific Reconstruction of Cuboid FracturesMed Sci Monit In Press; DOI: 10.12659/MSM.947437
Laboratory Research
Retention of 3-D-Printed, Milled, and Conventionally Fabricated Occlusal SplintsMed Sci Monit In Press; DOI: 10.12659/MSM.947342
Review article
A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitor...Med Sci Monit In Press; DOI: 10.12659/MSM.949300
Most Viewed Current Articles
17 Jan 2024 : Review article 7,932,846
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,905
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 29,808
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 23,790
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912